Sputnik V approved for use in Angola, Congo and Djibouti

Sputnik V approved for use in Angola, Congo and Djibouti

Moscow, March 3, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the approval of the Russian Sputnik V vaccine against coronavirus by regulatory authorities of the Republic of Angola, the Republic of the Congo and the Republic of Djibouti.

Sputnik V has been registered under the emergency use authorization procedure. It is now approved for use in 42 countries globally with total population of over 1.1 billion people.

Sputnik is one of the world's top three coronavirus vaccines in terms of the number of approvals issued by government regulators.

Sputnik V had been approved earlier in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Republika Srpska (entity of Bosnia and Herzegovina), Lebanon, Myanmar, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Kazakhstan, Uzbekistan, Gabon, San-Marino, Ghana, Syria, Kyrgyzstan, Guyana, Egypt, Honduras, Guatemala, Moldova and Slovakia.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:

“Vaccination is the main driver for overcoming the pandemic. Registration of Sputnik V in Angola, Djibouti and Congo will provide our partners with access to a safe and effective vaccine, which is highly trusted and used around the world. Diversification of national vaccine portfolios through registration of Sputnik V is an important example of international cooperation aimed at a major goal of saving lives.”

Sputnik V has a number of key advantages:

·        Efficacy of Sputnik V is 91.6% as confirmed by the data published in the Lancet, one of the world's oldest and most respected medical journals; it is one of only three vaccines in the world with efficacy of over 90%; Sputnik V provides full protection against severe cases of COVID-19.

·        The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.

·        Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

·        The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.

·        The developers of the Sputnik V vaccine are working collaboratively with AstraZeneca on a joint clinical trial to improve the efficacy of AstraZeneca vaccine.

·        There are no strong allergies caused by Sputnik V.

·        The storage temperature of Sputnik V at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.